secwatch.observer — SEC 8-K summary
======================================

Issuer:     Terns Pharmaceuticals, Inc. (TERN)
CIK:        0001831363
Form:       8-K
Filed at:   2024-09-09T23:59:59+00:00
Accession:  0000950170-24-104550
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Terns Pharma reports positive Phase 1 data for oral GLP-1R agonist TERN-601; max placebo-adjusted weight loss 4.9%
--------------------------------------------------------------------------------

- TERN-601 achieved 4.9% placebo-adjusted mean weight loss at 740 mg QD over 28 days (p<0.0001); 5.5% absolute mean loss.
- 67% of top-dose participants lost ≥5% baseline body weight; no treatment-related dose interruptions or discontinuations.
- Over 95% of AEs were mild; all GI events mild-to-moderate; no serious AEs or clinically meaningful lab/vital changes.
- Company plans to initiate Phase 2 in 2025, with optimal dose range identified and no additional dose exploration needed.
- Terns highlights distinct drug properties (low solubility, high gut permeability, low free fraction) as potential advantages over other oral GLP-1R agonists.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831363/000095017024104550/0000950170-24-104550-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831363/000095017024104550/tern-20240909.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-104550

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer